Identification of Demographic and Clinical Features Associated with Multi-Biologic Failure in the CorEvitas Psoriasis Registry
September 2023
in “
Journal of the American Academy of Dermatology
”
TLDR Certain factors like being female, having high cholesterol, using Medicaid, and previous non-biologic treatments increase the risk of multiple biologic failures in psoriasis patients.
The study aimed to identify risk factors for multiple biologic failure (MBF) in psoriasis patients using data from the CorEvitas Psoriasis Registry. Among 1,039 biologic-naïve patients, 65 (6%) experienced MBF, while 490 (47%) had a good response (GR) to treatment. The study found that female sex, hyperlipidemia, Medicaid insurance, and prior non-biologics use were independently associated with MBF. Additionally, the year of first biologic use and shorter psoriasis duration were linked to MBF, suggesting trends in biologic availability. These findings highlight a subset of psoriasis patients who may require more intensive monitoring and follow-up.
